Open AccessThe Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma
Author(s) -
S. Andrew Skillington,
Dorina Kallogjeri,
James S. Lewis,
Jay F. Piccirillo
Publication year - 2016
Publication title -
jama otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.571
H-Index - 128
eISSN - 2168-619X
pISSN - 2168-6181
DOI - 10.1001/jamaoto.2016.3353
Subject(s) - medicine , oncology , adjuvant chemotherapy , basal cell , chemotherapy , adjuvant , cancer , breast cancer
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has a favorable prognosis, and p16 immunohistochemistry is a surrogate marker of high-risk HPV infection and strong prognosticator. Given this favorable prognosis, treatment de-escalation for p16-positive OPSCC is now being considered with the goal of decreasing treatment-associated morbidity without compromising tumor control. The role of adjuvant chemotherapy in this setting is becoming increasingly unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom